Slide 1: Orion Interim Report 1-9/2020
Orion Interim Report 1−9/2020
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Highlights in January-September 2020
Highlights in January-September 2020
Slide 4: Orion is prepared for the second wave of COVID-19 pandemic
Orion is prepared for the second wave of COVID-19 pandemic 1 Orion is prepared for the second wave of the COVID-19 by seeking to ensure the 3 REFALS study (ODM-109) did not meet its endpoints. continuity of the production and the availability of pharmaceutical products by eg. 4 increasing inventorie
Slide 5: New Proprietary Products and R&D pipeline as growth drivers
New Proprietary Products and R&D pipeline as growth drivers – after ODM-109 failure more emphasis on other opportunities OPPORTUNITIES THREATS/CHALLENGES Darolutamide Generic mHSPC* competition Easyhaler® tiotropium* ODM-109* Animal Health R&D* Pricing pressure In-licensing and product acquisitions
Slide 6: COVID-19 pandemic impacts on Orion
COVID-19 pandemic impacts on Orion The most important thing is to take care of the health and safety of employees, the continuity of production and patient safety in ongoing clinical trials. Disruptions in the global supply The March demand spike impact chains possible but the risk of of Gx and OTC
Slide 7: Key figures 1−9/2020
Key figures 1−9/2020 Net sales Operating profit Operating profit Cash flow per share margin before financial items 823 246 30% 1.52 MEUR (776) MEUR (198) (25%) EUR (1.28) +6% +24% +18% Interim Report 1-9/2020 © Orion Corporation 21 October 2020 7
Slide 8: Development of net sales in 1-9/2020 vs. 1-9/2019
Development of net sales in 1-9/2020 vs. 1-9/2019 9 -8 21 823 11 2 13 776 -11 10 * Nubeqa® product sales & royalty ** Royalties & milestones (without Nubeqa® royalties) Interim Report 1-9/2020 © Orion Corporation 21 October 2020 8
Slide 9: Development of operating profit in 1-9/2020 vs. 1-9/2019
Development of operating profit in 1-9/2020 vs. 1-9/2019 19 -10 246 -4 2 6 34 198 * Product & service sales without sales margin and product mix change and exchange rate effect *** Exchange rate effect on gross margin ** Product sales margin and product mix change but without exchange rate effect In
Slide 10: Geographical breakdown and development of net sales
Geographical breakdown and development of net sales 1-9/2020 MEUR 1-9/2020 1-9/2019 13% 350 29% +14% 300 8% +3% 250 281 247 233 226 200 +3% 150 +27% -24% 134 130 16% 100 109 34% 88 86 50 67 Finland Scandinavia 0 Other Europe North America ROW Interim Report 1-9/2020 © Orion Corporation 21 October 20
Slide 11: All units showed growth
All units showed growth 1−9/2020 1−9/2019 1-9/2020 MEUR +6% 450 +8% 7% 400 372 8% 349 331 350 308 300 40% 250 200 +7% +4% 150 45% 100 69 64 56 54 50 0 Proprietary Products Specialty Proprietary Animal Fermion and Specialty Products Products Products Health Contract Manufacturing Animal Health Fermio
Slide 12: Best-selling pharmaceuticals 1−9/2020
Best-selling pharmaceuticals 1−9/2020 Net sales Change vs. . Indication EUR million 1−9/2019 1. Asthma, COPD 88 +17% 2. Parkinson’s disease 80 +14% 3. Acute heart failure 49 -1% 4. Intensive care sedative 41 -10% 5. Animal sedatives 29 +6% 6. Inflammatory pain 18 -3% 7. Divina series Menopausal symp
Slide 13: Proprietary Products
Proprietary Products
Slide 14: Easyhaler® franchise and Parkinson’s franchise growth drivers
Easyhaler® franchise and Parkinson’s franchise growth drivers Proprietary Products MEUR +17% +9% sales split 1-9/2020 100 +14% 88 90 80 22% 75 24% 80 70 73 -1% -10% 67 70 60 49 49 46 50 41 40 30 15% 20 10 27% 0 12% Easyhaler® Parkinson's Simdax® Dexdor® Others Parkinson's Easyhaler® franchise franch
Slide 15: Easyhaler® sales +17%
Easyhaler® sales +17% 1-9/2020 Budesonide-formoterol Easyhaler® MEUR 55 (44) +24% 40 1-9/2020 Other Easyhaler® products MEUR 33 (31) +6% 30 Sales, MEUR 20 10 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2015 2016 2017 2018 2019 2020 Other Budesonide-formoterol Easyhaler® In
Slide 16: Parkinson’s franchise sales +14%
Parkinson’s franchise sales +14% 1-9/2020 Own sales MEUR 39 (33) +16% 50 45 1-9/2020 Deliveries to partners MEUR 42 (37) +12% 40 35 Sales, MEUR 30 25 20 15 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2015 2016 2017 2018 2019 2020 Orion own sales Deliveries to partners
Slide 17: Dexdor® and Simdax®
Dexdor® and Simdax® 1-9/2020 Dexdor® MEUR 41 (46) -10 % 1-9/2020 Simdax® MEUR 49 (49) -1 % 20 20 15 15 10 10 5 5 0 0 2015 2016 2017 2018 2019 2020 2015 2016 2017 2018 2019 2020 Interim Report 1-9/2020 © Orion Corporation 21 October 2020 17
Slide 18: Specialty Products
Specialty Products
Slide 19: Specialty Products: COVID-19 related demand spike levelled off further
Specialty Products: COVID-19 related demand spike levelled off further Development of net sales Net sales by region Net sales by products 1−9/2020 1−9/2020 MEUR +3% 4% 250 15% 205 199 24% 200 14% 150 -7% +8% 55% 100 61 65 52 48 50 16% 72% 0 Finland Scandinavia Eastern Finland Generic drugs Europe &
Slide 20: In Finland, market for reference priced prescription drugs levelled off
In Finland, market for reference priced prescription drugs levelled off after demand spike in March The market for reference priced The sales of Orion's reference prescription drugs in Finland priced prescription drugs (1−9/2020) in Finland MEUR 340 (339) MEUR 84 (83) Market development Orion’s deve
Slide 21: Orion is strong in home market Finland
Orion is strong in home market Finland Human pharma market in Finland 1−9/2020 Reference Self-care Medicinal and non-medicinal products priced products in hospital and pharmacy channels: EUR 2,121 million prescription Orion market share in MEUR drugs pharmacy 250 229 Orion market share in 200 76 pha
Slide 22: Research and development
Research and development
Slide 23: Orion's key clinical drug development projects
Orion's key clinical drug development projects Project Indication Phase Registration Easyhaler® tiotropium COPD Bioequivalence study Darolutamide 1) Prostate cancer (mHSPC) I II III ODM-203 (targeted FGFR+VEGFR Solid tumours I II inhibitor) 2) ODM-207 (BET protein inhibitor) 2) Cancer I ODM-208 (CYP
Slide 24: Orion's key business targets in 2020
Orion's key business targets in 2020 Commercialisation of darolutamide in • First commercial sales of Europe. ARASENS trial (metastatic prostate darolutamide in Japan and the EU. 1. cancer) continues in order to expand the • Fully recruited ARASENS trial indication for the molecule. estimated to com
Slide 25: Orion's key business targets in 2020
Orion's key business targets in 2020 Strengthening Orion’s position as the most • Orion is a clear market leader significant provider of generic drugs in both in self-care products and 3. Finland. Competitive product portfolio in reference priced prescription Specialty Products and strengthening of
Slide 26: Orion’s preparedness for the second wave of COVID-19
Orion’s preparedness for the second wave of COVID-19 MATERIAL THEMES OF SUSTAINABILITY Ensuring patient safety and reliable supply of Responsibility for employees, the environment medications and the ethics and transparency of operations • Ensuring reliable supply of medications is the most • Taking
Slide 27: Outlook
Outlook
Slide 28: Outlook for 2020
Outlook for 2020 (provided on 19 October 2020) Net sales Orion estimates that in 2020 net sales will be at a similar level as in 2019 or slightly higher than in 2019 (net sales in 2019 were EUR 1,051 million). Operating profit Operating profit is estimated to be higher or clearly higher than in 2019
Slide 29: Orion calendar
Orion calendar Financial Statement Release for 2020 9/2/2021 AGM planned to be held 25/3/2021 Interim Report 1-3/2021 27/4/2021 Half-Year Financial Report 19/7/2021 Interim Report 1-9/2021 20/10/2021
Slide 30: Building well-being
Building well-being GRIoN Building well-being (ees